Navigation Links
InterMune Announces Start of Phase 1b Trial of ITMN-191
Date:9/26/2007

- Reports Further Details from Phase 1a SAD Clinical Study -

BRISBANE, Calif., Sept. 26 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) announced that the company has begun dosing the first patients in their Phase 1b multiple ascending dose (MAD) clinical trial evaluating ITMN-191 (also called R7227) in patients with chronic hepatitis C. ITMN-191 is a hepatitis C virus (HCV) protease inhibitor in development by InterMune and its partner, Roche. InterMune also reported additional information from its recently completed Phase 1a clinical trial of ITMN-191.

Dan Welch, President and Chief Executive Officer of InterMune, said, "We are pleased to have successfully initiated the very important Phase 1b multiple ascending dose study of ITMN-191." Mr. Welch continued, "This is our first opportunity to evaluate the effects of ITMN-191 on viral kinetics in HCV patients, and to gather additional safety information beyond the recently completed Phase 1a SAD study. We look forward to sharing top-line results from the three treatment-nave dose cohorts of the Phase 1b study in the first quarter of 2008."

Phase 1b Trial Design

The Phase 1b placebo-controlled study is anticipated to enroll approximately 40 HCV patients. The study will assess the effect of multiple doses of ITMN-191 given as a monotherapy on viral kinetics, viral resistance, pharmacokinetics, safety and tolerability. Patients will be administered ITMN-191 twice per day (BID) or three-times per day (TID) with a meal for a period of 14 days. Three ascending dose cohorts of treatment-naive chronic hepatitis C patients infected with HCV genotype 1 will be enrolled. In addition, a single cohort of treatment-experienced chronic hepatitis
'/>"/>

SOURCE InterMune, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. InterMune Presents Research on ITMN-191 in Hepatitis C at Digestive Disease Week Meeting
2. InterMune Presents Research on ITMN-191 in Hepatitis C at EASL Annual Meeting
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Sygnis Pharma AG announces date for presentation of clinical results
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... A lot of discussion in the medical community revolves ... injuries, or conditions. As medical science advances, doctors and surgeons ... that they consider to be more cutting edge. Yet, when ... method of treatment that stands out as the best solution ...
(Date:1/23/2015)... 2015  Northwest Biotherapeutics, Inc. (NASDAQ: NWBO )("NW Bio"), ... operable and inoperable solid tumor cancers, announced today that CEO ... Annual Phacilitate Immunotherapy Forum in Washington D.C. ... take place on January 26 at 10:30 a.m. EST at ...
(Date:1/23/2015)... Feffer LLP ( www.hfesq.com ) is investigating potential claims ... or the "Company") (NASDAQ: ADXS ), concerning ... shareholders. On January 21, 2015, an article ... had misrepresented the clinical data for its ADXS-HPV drug ...
Breaking Medicine Technology:No One-Size-Fits-All Remedy for Hernia Correction 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2
... , First-of-its-Kind Study Demonstrates REMICADE More Likely to Maintain ... , , CHICAGO, June 2 New ... with moderately to severely active Crohn,s disease having inadequate ... biologic therapy, were presented at Digestive Disease Week today. ...
... Insights into the Prediction of IBD Using Serology Testing ... Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic ... important serologic marker used in the detection of Crohn,s ... for celiac disease. In an oral presentation yesterday at ...
Cached Medicine Technology:New One-Year Data from REMICADE(R) SONIC Trial Show Sustained Efficacy Compared with Azathioprine in Treatment of Crohn's Disease 2New One-Year Data from REMICADE(R) SONIC Trial Show Sustained Efficacy Compared with Azathioprine in Treatment of Crohn's Disease 3New One-Year Data from REMICADE(R) SONIC Trial Show Sustained Efficacy Compared with Azathioprine in Treatment of Crohn's Disease 4New One-Year Data from REMICADE(R) SONIC Trial Show Sustained Efficacy Compared with Azathioprine in Treatment of Crohn's Disease 5New One-Year Data from REMICADE(R) SONIC Trial Show Sustained Efficacy Compared with Azathioprine in Treatment of Crohn's Disease 6New One-Year Data from REMICADE(R) SONIC Trial Show Sustained Efficacy Compared with Azathioprine in Treatment of Crohn's Disease 7New One-Year Data from REMICADE(R) SONIC Trial Show Sustained Efficacy Compared with Azathioprine in Treatment of Crohn's Disease 8New One-Year Data from REMICADE(R) SONIC Trial Show Sustained Efficacy Compared with Azathioprine in Treatment of Crohn's Disease 9Prometheus Announces New Findings Regarding Patients at Risk for Celiac Disease at DDW 2Prometheus Announces New Findings Regarding Patients at Risk for Celiac Disease at DDW 3
(Date:1/22/2015)... January 23, 2015 Angelweddingdress is a famous ... invites its customers to follow it on Facebook, Twitter, and ... Valentine’s Day gift. Angelweddingdress draws a lottery every week. , ... to Feb. 28, 2015. Click Angelweddingdress homepage for ...
(Date:1/22/2015)... 23, 2015 AngelWeddingDress, the premier women’s ... maternity wedding dresses. View website of AngelWeddingDress.com ... for maternity wedding dresses online for a bridal party. ... high quality for them. Its maternity wedding dresses are ...
(Date:1/22/2015)... January 22, 2015 Juvent Sports ( ... the 2015 PGA Merchandise Show to bestow a Juvent ... female amateur golfer, Arlene McKitrick. The award commemorated and ... golf tournament win. She won her first amateur tournament ...
(Date:1/22/2015)... New York, New York (PRWEB) January 22, 2015 ... filed after Fresenius Medical Care recalled its GranuFlo ... the federal multidistrict litigation underway in U.S. District Court, ... an Order dated January 20th, the Court has remanded ...
(Date:1/22/2015)... 2015 For over 20 years, Dr. David Cruz ... Vista area has treated just about every type of injury ... And for those same twenty-plus years, the team at ... injuries with the best possible doctor. With the combined ...
Breaking Medicine News(10 mins):Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2
... giants Cadbury have to pay heavily for the salmonella ... failed to inform the concerned authority about the possible ... of chocolates at their factory. They had supplied these ... many consumers. This was the breach of General Food ...
... It is a known fact that alcohol abuse and/or ... damage. //It is also known that women, more than ... a shorter period of drinking and with less overall ... also sustain greater cognitive damage than male alcoholics. ...
... achieving one of today’s Science greatest goals: allowing humans to ... well as from the UGR, researchers from the Spanish universities ... in this study, concluding that the consumption of melatonin – ... and present in many types of food – delays the ...
... has lodged a complaint with the West Bengal Human ... a patient died because the management// allegedly stopped medication ... 57, died on Saturday at the Mission of Mercy ... April 18 with diabetes, abdominal problem and cardiac ailments. ...
... Rajasthan will be fitted with an electronic biometric attendance system ... initially installed in a few primary schools, but later will ... first be installed in 15 schools of Jaipur and five ... already reached Bikaner. Initially, it would be used on an ...
... article published by the British Medical journal reveals that there has ... in the Asian region. This has become a// major strain on ... report the number of cases are expected to climb at the ... 156 to 100,000 as compared to 164 to 100,000 in the ...
Cached Medicine News:Health News:Cadbury Indicted on Salmonella Scare 2Health News:Cognitive Problems Occur More Rapidly in Female Alcoholics Than in Males 2Health News:Cognitive Problems Occur More Rapidly in Female Alcoholics Than in Males 3Health News:High Melatonin can Help Delay Ageing 2Health News:NRI Doctor Protests Patient's Death in Kolkata Hospital 2Health News:Cancer Time Bomb Threatening Economic Infrastructure 2